Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy
The DOI matches its Crossref record.
Abstract
OBJECTIVES: Dermatologists and rheumatologists have differed in their use of serial liver biopsy and liver function tests (LFT) to monitor the risk of hepatic fibrosis in long-term MTX therapy. It is judged safe to monitor LFT only in RA. Whilst there are few studies in PsA to justify this approach, it is widely used in rheumatology practice. The study aimed to assess prevalence of hepatic fibrosis in both psoriasis and PsA patients on long-term MTX therapy. METHODS: A prospective study of 54 patients with psoriatic disease had a liver biopsy according to dermatology guidelines on long-term MTX treatment with full assessment of risk factors. Previously, monitoring these patients was in accordance with ACR guidelines with 3-monthly LFT. RESULTS: MTX treatment duration was a mean of 6.9 years, with a mean cumulative dose of 4396 mg. There were no cases of advanced fibrosis or of cirrhosis and mild early fibrosis in 11 (22%) patients. The presence of early mild changes was related to the number of risk factors that the patient had for hepatic fibrosis [also the risk factors for non-alcoholic steatohepatitis (NASH)]. Pro-collagen 3 N-terminal peptide (PIIINP) was unhelpful in PsA and frequently elevated despite normal liver biopsy. CONCLUSIONS: Despite other risk factors for NASH, monitoring for hepatic fibrosis using serial liver function and ACR guidelines tests alone as in RA appears safe in psoriasis and PsA. Liver biopsy ought to be considered to assess the liver if LFT are persistently elevated. PIIINP is misleading in active PsA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Preventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy
Järveläinen, H., Sainio, A., Koulu, M., Wight, T. N., & Penttinen, R. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001289 · Cited by 566
Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro
Leite, S. B., Roosens, T., El Taghdouini, A., Mannaerts, I., Smout, A. J., Najimi, M., Sokal, E., Noor, F., Chesne, C., & van Grunsven, L. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.026 · Cited by 234
Luo, Y., Oseini, A., Gagnon, R., Charles, E. D., Sidik, K., Vincent, R., Collen, R., Idowu, M., Contos, M. J., Mirshahi, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30457-y · Cited by 74
Frankowski, M., Świerkot, J., Gomułkiewicz, M., Korman, L., Skoczyńska, M., & Starba, A. (2022) · Rheumatology International · doi:10.1007/s00296-021-05059-z · Cited by 11
Metadata
- Authors
- Lindsay, K., Fraser, A. D., Layton, A., Goodfield, M., Gruss, H., & Gough, A.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-24
- Volume
- 48
- Issue
- 5
- Pages
- 569-572
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2137203424
- Cited by
- 84
- References
- 0
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. https://app.cochat.ai/papers/10.1093/rheumatology/kep023
- The paper
- Lindsay, K., Fraser, A. D., Layton, A., Goodfield, M., Gruss, H., & Gough, A. (2008). Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology. https://doi.org/10.1093/rheumatology/kep023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.